MoonLake Immunotherapeuti... (MLTX)
NASDAQ: MLTX
· Real-Time Price · USD
9.89
-0.25 (-2.47%)
At close: Oct 15, 2025, 3:59 PM
9.86
-0.31%
After-hours: Oct 15, 2025, 04:31 PM EDT
-2.47% (1D)
| Bid | 9.89 |
| Market Cap | 628.03M |
| Revenue (ttm) | 101.85K |
| Net Income (ttm) | -176.47M |
| EPS (ttm) | -2.79 |
| PE Ratio (ttm) | -3.54 |
| Forward PE | -2.9 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 10.1 |
| Volume | 5,888,276 |
| Avg. Volume (20D) | 3,914,126 |
| Open | 10.15 |
| Previous Close | 10.14 |
| Day's Range | 9.48 - 10.25 |
| 52-Week Range | 5.95 - 62.75 |
| Beta | 1.10 |
| Ex-Dividend Date | n/a |
About MLTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MLTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MLTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-89.92%
MoonLake Immunotherapeutics shares are trading low...
Unlock content with
Pro Subscription
4 months ago
+17.95%
MoonLake Immunotherapeutics shares are trading higher following reports that Merck is looking to acquire the company in a deal valued at over $3 billion.
6 hours ago · businesswire.com
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTXLOS ANGELES--(BUSINESS WIRE)--MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX.
6 hours ago · businesswire.com
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES--(BUSINESS WIRE)---- $MLTX--MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm.
2 weeks ago · proactiveinvestors.com
MoonLake Immunotherapeutics analysts slash target price as trial results disappointRBC analysts cut their target price on MoonLake Immunotherapeutics (NASDAQ: MLTX) to $10 per share, from $67 previously, after the biotechnology company reported trial results for its highly anticipat...
